- Ankylosing spondylitis
- Dactylitis
- IBD-associated arthritis
- Psoriatic arthritis
- Reactive arthritis
- Reiter's syndrome
- Rheumatology-related Crohn's disease
- Spondylarthritis
Alexis R. Ogdie, MD, MSCE
Rheumatology
Accepting new patients
Sees patients age 18 and up
Penn Rheumatology Perelman
Penn Medicine Provider
About me
- Director, Center for Clinical Epidemiology and Biostatistics
- Director, Penn Psoriatic Arthritis and Spondyloarthritis Program
- Professor of Medicine (Rheumatology) at the Hospital of the University of Pennsylvania
- Associate Professor of Epidemiology in Biostatistics and Epidemiology
- Professor of Biostatistics and Epidemiology
Dr. Ogdie's research program is focused on inflammatory arthritis (IA) including psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), and rheumatoid arthritis (RA). The mission of her research program is to improve outcomes in IA by accelerating diagnosis, increasing the focus on meaningful, patient-centered outcomes, and developing and advancing methods for precision medicine. Dr. Ogdie is an expert in the care of patients with IA, Director of the Penn Psoriatic Arthritis and Spondyloarthritis Program and Director of the Penn Center for Clinical Epidemiology and Biostatistics.
Her areas of expertise include epidemiology and pharmacoepidemiology, biostatistical methods for observational studies (e.g., complex time to event modeling, prediction modeling), outcome measures (e.g., qualitative and quantitative/psychometric assessment), clinical trial design and more general qualitative methods (e.g., survey, focus group and interview studies). Her recent work has focused on a) pragmatic trial design and implementation including the recent launch of a first head-to-head pragmatic trial in PsA (EVOLUTION, NCT05669833); b) trials aimed at improving outcomes in PsA through holistic care including a trial to test Dietary Interventions in PsA (DIPSA, NCT04180904), and a new single arm trial to address whole patient care as a novel care paradigm in rheumatology (funded by a Rheumatology Research Foundation) and c) identifying risk factors for development of PsA among patients with psoriasis.
My education and training
- Medical School: Georgetown University School of Medicine
- Residency: University of Pennsylvania Health System
- Fellowship: University of Pennsylvania Health System
Spoken languages
English
English
Reviews
253 reviews
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Insurance accepted
Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.
- Aetna Advantra Cares D-SNP
- Aetna Advantra Credit Value
- Aetna Advantra Eagle HMO
- Aetna Advantra Eagle POS
- Aetna Advantra Premier Plus PPO
- Aetna Advantra Value
- Aetna Advantra Value Plus
- Aetna APCN Plus (Multi-Tier)
- Aetna Better Health Kids (CHIP) - DH Only
- Aetna Flexible Five
- Aetna Freedom Core
- Aetna Gold
- Aetna HMO
- Aetna Philly Prime
- Aetna POS
- Aetna PPO APCN
- Aetna Premier
- Aetna Premier Plus
- Aetna Savings Plus
- Aetna Signature Administrators
- Aetna Student Health Plan PPO
- Aetna Upfront Advantage
- First Health HMO
- First Health POS
- First Health PPO
- Meritain - Aramark (Other)
- Meritain - Aramark (Pennsylvania Premier Medical Plan)
- Americhealth Caritas of PA VIP - LGH Only
- Amerihealth Caritas (Transplant patients only)
- Amerihealth Caritas of PA - LGH Only
- Centivo EPO
- Cigna Healthcare EPO
- Cigna Healthcare HMO
- Cigna Healthcare POS
- Cigna Healthcare PPO
- Claim Watcher (Homestead/ INDECs) Open Access
- Clover Health Choice
- Clover Health Choice Value PPO
- Clover Health Classic HMO
- Clover Health Value
Locations
Penn Medicine hospital privileges
- Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
- Pennsylvania Hospital: Has privileges to treat patients in the hospital.
- Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Qualifications and experience
- Rheumatology, 2011
- American College of Rheumatology, National
- Forward/National Databank for Rheumatic Diseases, National
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis, International
- International Society for Pharmacoepidemiology, International
- iPROLEPSIS advisory board, Athens, Greece, International
- National Psoriasis Foundation, National
- Penn Center for Musculoskeletal Disorders (PCMD), Local
- Penn Center for Pharmacoepidemiology Research and Training (CPeRT), Local
- Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN), National
- Rheumatology Research Foundation, National
- Spondyloarthritis Research and Treatment Network, National
Treatments and conditions
Research
Publications
Ramiro S, Gaillez C, Kiltz U, Gensler LS, Pisal C, Braun J, Ogdie A. No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials , Arthritis Res Ther: 2026
Romich E, Ogdie A, Stephens-Shields A, Merkel PA, Assassi S, Bernstein EJ, Bujor A, Castelino FV, Chung L, Evnin LB, Frech TM, Gordon JK, Griffith M, Hant FN, Harding ML, Hummers LK, Khanna D, Lakin KS, Lebiedz-Odrobina DJ, Luo Y, Makol A, Mayes MD, McMahan ZH, Molitor J, Moore DF, Paik J, Richardson C, Skaug B, Shah AA, Shah A, Steen V, VanBuren JM, Volkmann ER, Zahn C, Sandorfi N; CONQUER Investigators. Discordance between patient and physician global assessments in early systemic sclerosis , Arthritis Care Res (Hoboken): 2026
Baker JF, Wysham KD, Quinones M, England BR, Jin K, Olave M, Wetzel S, Gillcrist RL, Lavery C, Keller N, Kramer B, Ateh B, Brubeck H, White DK, Ogdie A, Xiao R, Neogi T, Scanzello CR. Behavioral Incentives for Exercise and Intra-Articular Corticosteroids for Knee Osteoarthritis: Results from a Factorially Designed Pragmatic Randomized Clinical Trial , Arthritis Rheumatol: 2026
Nikiphorou E, Ogdie A, Twigg D, Quiñones E, Ling YL, Cappelleri JC, Sanchez-Riera L, Masri KR, Hughes M, Massey N. Treatment satisfaction, disease severity, and health-care use in patients with axial spondyloarthritis in the United States and Europe , Rheumatology (Oxford), 65: 2026,keag106
Merola JF, Mease P, Kivitz A, Sattar N, Coates LC, Aletaha D, Kartman CE, Fischer P, Sun L, Martínez-Osuna P, Kronbergs A, Prajapati P, Cardoso A, Genovese MC, Ogdie A. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial , Arthritis Rheumatol: 2026
Ogdie A, Middaugh N, Marchese M, Walsh JA, Bello N, Ngantcha M, Kronbergs A, Grace EL, Mease PJ. Cycling to TNFi vs. Switching to IL-17Ai Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World CorEvitas PsA/SpA Registry Data , Adv Ther: 2026
Ogdie A, Merola JF, Mease PJ, Ritchlin CT, Scher JU, Lafferty KP, Chan D, Chakravarty SD, Langholff W, Wang Y, Shao J, Krol Y, Gottlieb AB. Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of the Phase 3, Randomized, Placebo-Controlled SOLSTICE Study , Arthritis Rheumatol: 2026
Mease P, Ye X, Saffore CD, Parikh B, Ciecinski S, Blachley T, Eliot M, Middaugh N, Ogdie A. Quantifying Disease Activity Despite Treatment with Tumor Necrosis Factor Inhibitors Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World Results from the PPD CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry , Rheumatol Ther: 2026
Leung YY, Haugegaard T, Annfeldt TK, Holland R, Strand V, Mease P, Tugwell P, Wells GA, Shea BJ, Mathew AJ, Goel N, Lindsay C, Ogdie A, Orbai AM, Coates LC, Gladman DD, Tillett W, Chau J, Christensen R. Determining the best discriminatory physical functioning outcome measurement instrument for psoriatic arthritis trials: A meta-epidemiological study , Semin Arthritis Rheum: 2026
Gladman DD, Eder L, Selmi C, Mease PJ, Ogdie A, Lozenski K, Adamson E, Sharaf M, Rampakakis E, Pina Vegas L, Coates LC. Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials , Rheumatol Ther: 2025